Aromatase inhibitors demonstrated superior disease-free survival and time to distant recurrence compared to SERMs in HR+/HER2+ early breast cancer. The benefits of aromatase inhibitors were consistent ...
The "Port Digital-Twin Visualization Global Market Report 2025" has been added to ResearchAndMarkets.com's offering. The port digital-twin visualization market is poised for significant growth, ...
In the phase 3 COBRA trial, the carfilzomib/lenalidomide/dexamethasone regimen shows significant improvements in PFS and other outcomes in newly diagnosed MM, including in patients at cytogenic risk.
Consistently high efficacy was seen across subgroups with ORR of 96%-100% and three-year ongoing response rates of 60%-83%, including in patients with high-risk characteristics (progression of disease ...
Younger donor age (18-35) is crucial for stem cell transplant success and patient survival; superseding related sibling matches and older donor paradigms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback